Endometriosis is a chronic gynaecological disease affecting 1 in 10 reproductive-age women. It is defined as the presence of endometrium-like tissue outside the uterus. Beyond this placid anatomical definition, endometriosis is a complex, hormonal, inflammatory, and systemic condition that poses significant familial, psychological, and economic burden. The interaction between the cardiovascular system and endometriosis has become a field of interest as the underlying mutual mechanisms become better understood. On the basis of accumulating fundamental and clinical evidence, it is likely that there exists a close relationship between endometriosis and the cardiovascular system. Therefore, investigating the endometriosis—cardiovascular interaction is highly clinically significant. In this review, we highlight our current understanding of the pathophysiology of endometriosis with systemic hormonal, pro-inflammatory, pro-angiogenic, immunologic, and genetic processes beyond the peritoneal microenvironment. Additionally, we provide current clinical evidence about how endometriosis interacts with cardiovascular risk factors and cardiovascular disease (CVD). To date, only small associations between endometriosis and CVD have been reported in observational studies, inherently limited by the potential influence of unmeasured confounding. Cardiovascular disease in women with endometriosis remains understudied, under-recognized, and underdiagnosed. More detailed study of the cardiovascular-endometriosis interaction is needed to fully understand its clinical relevance, underlying pathophysiology, possible means of early diagnosis and prevention.
Keywords

Endometriosis • Cardiovascular disease • Heart disease • Women

Introduction

Endometriosis is a chronic gynaecological disease estimated to affect 10% of reproductive-age women. Recent insights have linked endometriosis to several pathological mechanisms ranging from systemic inflammation, pro-atherogenic lipid profile, and enhanced oxidative stress to endothelial dysfunction. Considered as a systemic disease, the pathogenesis of endometriosis and the impact of the disease remain poorly understood. Robust knowledge is restricted to data from women surgically diagnosed with endometriosis limiting the development of multidisciplinary approaches to ameliorate the substantial cumulative burden of this condition.

A focused update consensus document on gynaecological and obstetric conditions that impact cardiovascular risk in women was released in March 2021. The scarcity of a strong dataset limited the ability to provide clear evidence regarding the pathophysiology, pathogenesis, and prognosis of endometriosis in cardiovascular disease (CVD). Here, we review relevant evidence regarding the relationship between endometriosis and CVD.

The purpose of this review article is to further our understanding of the shared mechanisms underlying endometriosis and atherosclerotic CVD, by contextualizing biological pathways common to both diseases, addressing the association between cardiovascular risk factors and endometriosis, and finally, highlighting key clinical evidence that link endometriosis with adverse cardiovascular events.

Endometriosis: overview

Endometriosis: epidemiology, symptoms, diagnosis, and treatment

Endometriosis is estimated to affect 10% of reproductive-age women. The true prevalence of endometriosis remains unknown since historically, diagnoses have only been made using laparoscopy and more recently multimodal imaging techniques. Misdiagnosis remains common, and diagnosis is often largely delayed by years. Currently, the prevalence ranges from 2% to 11% among asymptomatic women, 5% to 50% among infertile women, and 5% to 21% among women with pelvic pain.

The most common signs and symptoms of endometriosis include chronic pelvic pain, dyspareunia, dysmenorrhoea, and infertility, although asymptomatic cases can arise. Subsequently, decreased quality of life, fatigue, depression, high analgesic consumption, and reduced work productivity may occur. Endometriosis poses a major economic burden, similar to diabetes, with an estimated annual cost per patient of €9579 (Figure 1). The condition presents with four phenotypes: superficial peritoneal lesions, ovarian endometriomas, deep infiltrating endometriosis, and extragenital areas including such as peripheral nerves as well as rectal, diaphragmatic, and pleural locations.

Because endometriosis manifests in a wide spectrum of severity, from asymptomatic cases to severe conditions, diagnosis is challenging and often delayed. Classical symptoms such as chronic pelvic pain,
dysmenorrhoea, and dyspareunia are non-specific and can overlap with other conditions involving the urinary or digestive tract. Key features of endometriosis can be identified during patient interviews through a family history of endometriosis, including a cyclic nature of pelvic pain, poor or no response to analgesics, severe primary dysmenorrhoea during adolescence and infertility.6 Although a normal physical examination does not rule out endometriosis, pelvic and rectal examination may detect infiltration and palpable sensitive areas involving the pelvic cavity (vagina, rectovaginal septum, uterosacral ligaments, and pouch of Douglas). The low diagnostic performance of physical examinations may improve during menstruation10,11 but a key step in diagnosis now involves non-invasive imaging techniques with transvaginal ultrasound12,13 and magnetic resonance imaging.14,15 Diagnosis of endometriosis should be based on patient interviews, examination and imaging, and surgery should be restricted to diagnostic uncertainty and persistent symptoms despite an optimal medical therapy.6 Currently available therapeutic approaches include medical treatment with non-hormonal (non-steroidal anti-inflammatory drugs) and hormonal treatments (combined oral contraceptives, progestins, and gonadotropin-releasing hormone analogues), surgery (conservative and definitive), and assisted reproductive technologies in patients with endometriosis-related infertility.

The pathobiology of endometriosis

The pathobiology of endometriosis is complex, and synergistic biological pathways are required to facilitate the establishment and persistence of endometriotic debris within the peritoneal cavity and ectopic regions. Endometriotic debris is characterized by epithelial, stromal, endothelial, glandular, and immune cell components with altered immunoinflammatory profiles compared with normal endometrium.16,17 A pro-inflammatory, pro-angiogenic, and aberrant immune-endocrine environment is required to facilitate the growth and survival of endometriotic lesions (Figure 2).

Immune cells are predominantly implicated in endometriosis pathogenesis, including neutrophils, macrophages, monocytes, and regulatory T cells. Intense neutrophil and macrophages infiltration has been observed in eutopic endometrium and the peritoneal fluid.18 At sites of inflammation, macrophages and mast cells drive neutrophil recruitment through the release of chemokines. A localized and systemic inflammatory response is observed in endometriosis, with elevated cytokine levels (IL-6, IL-8, IL-17, IL-33, TNF-a, etc.) in both the peritoneal fluid and plasma. Impaired T cell, B cell, mast cell, dendritic cell, and natural killer cell function influences disease establishment and progression.19 Collectively, this promotes aberrant local and systemic chronic inflammation. Angiogenesis is supported by damage-associated molecular patterns, such as high-mobility group box 1, IL-33 and other cytokines, and high VEGF expression. Local synthesis of oestradiol from endometriotic lesions combined with enhanced oestrogen receptor (OR) expression in endometriotic tissues contributes to disease progression. Enhanced OR expression has been associated with enhanced inflammatory activity through cytokine release, anti-apoptotic signalling, angiogenesis, and subsequent lesion growth.20,21 Endothelial cell damage, endothelial dysfunction, increased oxidative stress,22 and increased levels of microvesicles23 have been reported both at the site of endometriosis and in peripheral blood.

Most processes and biomarkers discussed in the pathobiology of endometriosis demonstrate compelling associations with atherosclerosis and CVD development in general. Future research is
necessary to clarify the mechanistic roles of these intercellular communication mediators in endometriosis relative to facilitating the development of other comorbid conditions (Figure 3).

Endometriosis and atherosclerosis

Endometriosis and atherosclerosis: shared pathophysiological mechanisms

The most widely accepted pathophysiological hypothesis for endometriosis is based on retrograde menstruation, which occurs in most patients.24 Menstrual blood containing endometrial cells flows back through the fallopian tubes and into the pelvic cavity, where the cells implant, develop, continue to thicken, and bleed over the course of each menstrual cycle. Alternative theories involving endometrial stem cells, stem cells from bone marrow, lymphovascular emboli of endometrial cells, and coelomic metaplasia have been proposed to explain the unusual locations of endometriosis.

Endometriosis and atherosclerosis are traditionally viewed as distinct entities, with endometriosis typically affecting young reproductive-age women, while atherosclerosis is an aging-related process. Recent insights have unveiled cellular and molecular overlaps between the two conditions. Chronic inflammation, enhanced oxidative stress, endothelial dysfunction, and cellular proliferation are the hallmarks of both atherosclerosis and endometriosis.24–28 The full spectrum of the pathogenesis and pathophysiology of endometriosis has been extensively detailed elsewhere,2,24,29 and it is now widely acknowledged that endometriosis is a multifactorial condition involving hormonal, pro-inflammatory, pro-angiogenic, immunologic, and genetic processes. Briefly, the hormone-dependent process and proliferation of endometrial fragments require oestradiol provided by systemic hormones and favoured by disrupted hormonal signalling pathways.30,31 Significant macrophage recruitment combined with intense activation of cytokines and pro-angiogenic factors facilitates neovascularization and ectopic lesion growth32,33 in an enhanced local and systemic pro-inflammatory environment.34,35 Building on this biological overlap between atherosclerosis and endometriosis, recent research has provided evidence supporting an association between atherosclerotic CVD and endometriosis. Increased arterial stiffness36 and impaired flow-mediated dilation,37,38 a surrogate marker of endothelial dysfunction potentially reversible after surgical treatment,39 were associated with endometriosis.

Figure 2 Molecular pathways underpinning endometriosis. Endometriotic lesions are characterized by a unique environment. The interplay between pro-inflammatory signals, pro-angiogenic signals, and a unique endocrine signature contribute to the pathogenesis of endometriosis. This schematic representation of the endometriotic lesion identifies three distinct molecular pathways that facilitate lesion growth in endometriosis. (1) Pro-inflammatory signals: increased neutrophil infiltration in the peritoneal fluid; increased macrophage populations in the peritoneal fluid and eutopic endometrium; elevated cytokine levels (IL-6, IL-8, IL-17, IL-33, TNF-a, etc.) in both the peritoneal fluid and plasma; at sites of inflammation, macrophages and mast cells drive neutrophil recruitment through the release of chemokines; impair regulatory T cells function. (2) Pro-angiogenic signals: Damage-associated molecular patterns: high-mobility group box 1, elevated IL-33 level, etc.; vascular endothelial growth factor. (3) Endocrine signals: local synthesis of oestradiol by endometriotic lesions; enhanced oestrogen receptor expression. ILs, interleukins; OR, oestrogen receptor; Treg cells, regulatory T cells; VEGF, vascular endothelial growth factor.
**Shared genetic susceptibility to endometriosis and atherosclerosis**

Recent advances have identified variants at CDKN2B-AS on chromosome 9p21 as a susceptibility locus for endometriosis and atherosclerotic phenotypes, such as intracranial aneurysm, abdominal aortic aneurysm, peripheral vascular disease, diabetes, and stroke. Similarly, locus 7q22 has been associated with endometriosis and CVD. CDKN2B-AS transcript levels are known to correlate with the severity of atherosclerosis, and a recently published genome-wide association study (GWAS) identified that rs10965235 single-nucleotide polymorphism (SNP) in the CDKN2B-AS gene is associated with endometriosis. Advances in GWASs and the application of SNPs in the identification of increased genetic susceptibility to CVD in women with endometriosis may be of particular interest in tomorrow’s research.

**Endometriosis and cardiovascular risk factors**

Cardiovascular risk factors are being increasingly recognized as having a significant association with endometriosis.

**Hypertension**

Pioneer work by Mu et al. found a strong association between endometriosis and hypertension. In a prospective cohort of 116,430 nurses between 25 and 42 years of age followed for 20 years, 4,244 women were diagnosed with laparoscopically confirmed endometriosis. After adjusting for cofounders, the relative risk (RR) for the development of hypertension was 1.14 [95% confidence interval (CI), 1.09–1.18] among women with endometriosis (Table 1). Conversely, the RR of developing laparoscopically confirmed endometriosis was 1.29 (95% CI 1.18–1.41) among hypertensive women. Several hypotheses for such associations have been proposed, starting with the inflammatory process surrounding endometriosis known for decades as a key component in the pathogenesis of hypertension. Overall, 30% of the reported association between endometriosis and hypertension was accounted for by treatment effects, namely hysterectomy/oophorectomy and earlier age of surgery. A decline in the production of sex hormones either in postmenopausal women or after ovariectomy is known to significantly increase the risk of hypertensive disorders. Non-steroidal anti-inflammatory drugs aimed to reduce pelvic pain are known to increase blood pressure and may be an important co-founder. Okoth et al. found an adjusted odds ratio (aOR) of 1.12 (95% CI 1.07–1.17) for hypertension among 56,090 women with endometriosis compared with 223,669 matched controls. Finally, endometriosis is an independent and significant risk factor for the occurrence of gestational hypertension-pre-eclampsia.

**Dyslipidaemia**

Observational studies have suggested a strong association between endometriosis and an enhanced atherogenic lipid profile. The most convincing evidence was provided by Mu et al. in Nurses’ Health Study II (NHSII; n = 116,430), with a 25% increased risk (95% CI...
| Author(s) | Study name | Location | Population | Design | Method of data collection | Ascertainment period (year) | Findings |
|-----------|------------|----------|------------|--------|---------------------------|----------------------------|----------|
| **Hypertension and gestational hypertension-pre-eclampsia** |
| Mu et al. | NHSII (Nurses’ Health Study II) | USA | 116,430 female nurses aged 25–42. 4,244 women with laparoscopically confirmed endometriosis and 91,554 control women | Prospective cohort study | Self-completed questionnaire | 1989–2009 | Hypertension (RR 1.14, 95% CI 1.09–1.18) |
| Nagai et al. | JNHS (Japan Nurses’ Health Study) | Japan | 49,927 female nurses aged 41.2 ± 7.9. Estimated age at peak incidence: 36 years of age and cumulative incidence at 50 years of age: 7.4% | Prospective cohort study | Self-completed questionnaire | 2001–07 | Hypertension (OR 1.26, 95% CI 1.07–1.47) |
| Okoth et al. | UK | Women aged between 16 and 50. 56,090 women with endometriosis and 223,669 matched control women | Population-based cohort study | Electronic health records | 1995–2018 | Gestational hypertension and/or pre-eclampsia (aHR 1.12, 95% CI 1.07–1.17) |
| Pan et al. | Taiwan | 63,000 women with endometriosis and 10,312 matched control women | Population-based cohort study | Electronic health records | 1998–2012 | Gestational hypertension and/or pre-eclampsia (aOR 2.27, 95% CI 1.76–2.93) |
| Lalani et al. | 33 studies; 280,488 patients | Meta-analysis of observational studies | | | 1990–2017 | Pre-eclampsia (OR 1.18, 95% CI 1.01–1.39); Gestational hypertension and/or pre-eclampsia (OR 1.21, 95% CI 1.05–1.39) |
| **Dyslipidaemia** |
| Mu et al. | NHSII (Nurses’ Health Study II) | USA | 116,430 female nurses aged 25 to 42. 4,244 women with laparoscopically confirmed endometriosis and 91,554 control women. 196,722 reported pregnancies | Prospective cohort study | Self-completed questionnaire | 1989–2009 | Hypercholesterolaemia (RR 1.25, 95% CI 1.21–1.30) |
| Nagai et al. | JNHS (Japan Nurses’ Health Study) | Japan | 49,927 female nurses aged 41.2 ± 7.9. Estimated age at peak incidence: 36 years of age and cumulative incidence at 50 years of age: 7.4% | Prospective cohort study | Self-completed questionnaire | 2001–07 | Hypercholesterolaemia (OR 1.30, 95% CI 1.16–1.45) |
| Tani et al. | Japan | 28 women with laparoscopically confirmed endometriosis. 21 control women | Case-control study | Laboratory data | August 2010 to May 2013 | Lower HDL-C (P < 0.01). No difference in TG; LDL-C |
| Santoro et al. | Italy | 37 women with laparoscopically confirmed endometriosis. 31 control women | Cross-sectional study | Laboratory data | July 2010 to June 2011 | Higher HDL-C (P = 0.045). No difference in TG; LDL-C |

*Continued*
| Author(s)         | Study name                        | Location | Population                                                                 | Design                      | Method of data collection | Ascertainment period (year) | Findings                                                                 |
|-------------------|-----------------------------------|----------|-----------------------------------------------------------------------------|-----------------------------|----------------------------|------------------------------|--------------------------------------------------------------------------|
| Melo et al.⁵¹     | 40 women with laparoscopically confirmed endometriosis. 80 control women | Brazil   | Cross-sectional study                                                      | Laboratory data             |                             |                              | Higher LDL-C ($P < 0.001$); higher TG ($P = 0.02$); higher HDL-C ($P = 0.008$) |
| Crook et al.⁵²    | 29 women with laparoscopically confirmed endometriosis. 29 controls | UK       | Case-control study                                                          | Laboratory data             |                             |                              | Higher TG level ($P < 0.02$) and LP(a) level ($P < 0.01$). No difference in LDL-C; HDL-C |
| Hopeman et al.⁵³  | 24 women with endometriosis. 181 infertile controls with in vitro fertilization | USA      | Cross-sectional study                                                      | Laboratory data             |                             |                              | Lower eicosapentaenoic acid ($P = 0.009$)                                |
| Kinugasa et al.   | 41 women with laparoscopically confirmed endometriosis. 28 control women | Japan    | Cross-sectional study                                                      | April 2009 to March 2010    |                             |                              | Higher asymmetric dimethylarginine (ADMA) level ($P = 0.04$). No difference in TG; HDL-C; LDL-C |
| Pretta et al.⁵⁴   | 66 women with laparoscopically confirmed endometriosis. 66 matched control women | Italy    | Case-control study                                                          | Laboratory data             | November 2006 to May 2007  |                              | No difference in TG; HDL-C; LDL-C                                      |
| Verit et al.⁵⁵    | 47 women with laparoscopically confirmed endometriosis. 40 matched control women | Turkey   | Case-control study                                                          | Laboratory data             |                             |                              | Higher TG; LDL-C ($P < 0.0001$); lower HDL-C ($P < 0.0001$)             |
| Obesity           | Ferrero et al.⁵⁶                   | Italy    | 366 women with laparoscopically confirmed endometriosis. 248 control women | Prospective cohort study    | Electronic health records  | August 2000 to February 2004 | Lower BMI (21.17 ± 2.86 vs. 22.33 ± 3.68, $P < 0.001$). No difference in BMI according to endometriosis stages and severity |
| Holdsworth-Carson et al. ⁵⁷ | 357 women with laparoscopically confirmed endometriosis. 152 control women | Australia | Retrospective case-control study | Electronic health records  | May 2012 to March 2016      |                              | Lower BMI (25.0 ± 0.3 vs. 27.2 ± 0.5, $P < 0.001$). Inverse relationship between BMI and frequency of endometriosis ($P < 0.001$) |
| Shah et al.⁵⁸     | NHSII (Nurses' Health Study II)   | USA      | 5504 incident cases of endometriosis during 1 299 349 woman-years (incidence rate = 385 per 100 000 woman-years) | Prospective cohort study    | Self-completed questionnaire | September 1989 to June 2011 | BMI at age 18 and current BMI: each significantly inversely associated with endometriosis ($P < 0.0001$) |

Continued
| Author(s) | Study name | Location | Population | Design | Method of data collection | Ascertainment period (year) | Findings |
|-----------|------------|----------|------------|--------|---------------------------|----------------------------|----------|
| Missmer et al. | NHSII (Nurses’ Health Study II) | USA | 1721 women with laparoscopically confirmed endometriosis | Prospective cohort study | Self-completed questionnaire | September 1989 to June 1999 | Inverse relation with BMI at age 18 years (for BMI of >20 vs. 19-20.4 kg/m²: OR 0.8, 95% CI 0.6-1.1; P = 0.004) |
| Hediger et al. | | USA | 32 women with laparoscopically confirmed endometriosis | Prospective cohort study | Self-completed questionnaire | April 1999 to January 2000 | Lower BMI (23.7 ± 3.8 vs. 26.9 ± 6.2, 95% CI P = 0.006). For every unit increase in BMI, 12–14% decrease in the likelihood of being diagnosed with endometriosis |
| Lafay Pirotta et al. | | France | 238 women with laparoscopically confirmed endometriosis | Case-control study | Self-completed questionnaire | February 2005 to October 2008 | Lower BMI (21.70 ± 3.7 vs. 23.29 ± 4, 95% CI P < 0.001) |
| Farland et al. | E3N (Teachers Health Study) | France | 9895 female teachers. 2416 women with laparoscopically confirmed endometriosis and 61208 control women. | Prospective cohort study | Self-completed questionnaire | | Odds of endometriosis were lower among women with a large vs. lean body size at 8 years (P = 0.003), at menarche (P < 0.0001), and at ages 20-25 years (P < 0.0001) |
| Liu et al. | | | | Meta-analysis of observational studies | | | 33% reduction in the risk of endometriosis for each 5 kg/m² increase in BMI (OR = 0.67, 95% CI 0.53-0.84), with statistically significant heterogeneity across the studies |
| Tang et al. | | China | 709 women with laparoscopically confirmed endometriosis | Retrospective case-control study | | | No difference in BMI (20.9 vs. 20.9, 95% CI P = 0.23) or 1.97% (95% CI 1.15-3.52, P = 0.0185) |

Continued
| Author(s)          | Study name                        | Location     | Population                                                                 | Design                          | Method of data collection         | Ascertainment period (year) | Findings                                                                 |
|-------------------|-----------------------------------|--------------|----------------------------------------------------------------------------|---------------------------------|----------------------------------|-----------------------------|--------------------------------------------------------------------------|
| **Tobacco smoking** | Cramer et al.                     | USA          | 317 women with laparoscopically confirmed endometriosis. 4023 control women | Prospective cohort study        |                                  | January 1981 to June 1983   | Decreased risk for endometriosis among smokers who began before age 17 years and ≥ one pack a day |
|                   | Calhaz-Jorge et al.               | Portugal     | 488 women with laparoscopically confirmed endometriosis. 591 control women | Prospective cohort study        |                                  | 1993–2000                   | Decreased risk for endometriosis: 1–10 cigarettes/day (OR 0.57, 95% CI 0.39–0.79); 11–20 cigarettes/day (OR 0.52, 95% CI 0.34–0.79); >20 cigarettes/day (OR 0.56, 95% CI 0.32–0.99) |
|                   | Bravi et al.                      | USA          | 38 studies; 13 129 women diagnosed with endometriosis                      | Meta-analysis of observational studies |                                  | Publications up to September 2014 | No evidence for an association between tobacco smoking and the risk of endometriosis. Non-smokers RR 0.96 (95% CI 0.86–1.08); Former smokers RR 0.95 (95% CI 0.81–1.11); Current smokers RR 0.92 (95% CI 0.82–1.04); Moderate smokers RR 0.87 (95% CI 0.70–1.07) and heavy smokers RR 0.93 (95% CI 0.69–1.26) |
| **Air pollution exposure** | Mahalingaiah et al.              | USA          | 2486 women with laparoscopically confirmed endometriosis, over 710 230 person-years of follow-up | Geographic information system software |                                  | 1993–2007                   | No association between endometriosis risk and distance to road or exposure to particulate matter |
| **Diabetes and gestational diabetes** | Farland et al.                  | USA          |                                                                  | Prospective cohort study        | Self-completed questionnaire      | 1989 to June 2017            | No association between endometriosis and risk of diabetes mellitus and gestational diabetes |
| Author(s)          | Study name                      | Location | Population                                                                 | Design                                                                 | Method of data collection | Ascertainment period (year) | Findings                                                                                                      |
|-------------------|---------------------------------|----------|-----------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------|
| Perea-López et al. | 112 037 female nurses. 5242 women with laparoscopically confirmed endometriosis and 106 795 control women |          |                                                                             | type 2 diabetes in multi-variable confounder-adjusted models (HR 1.06; 95% CI 0.98–1.13) or models accounting for potential mediating factors (HR 0.94; 95% CI 0.87–1.00) |                           |                            |                                                                             |
| B. Marchandot et al. | 12 studies; 48 762 pregnancies including 3 461 with endometriosis |          |                                                                             | No significant effect on gestational diabetes risk (OR = 1.14; 95% CI 0.86–1.51; P = 0.35, I² = 56%, Egger’s test P = 0.45) |                           |                            |                                                                             |

aHR, adjusted hazard ratio; BMI, body mass index; HDL-C, high-density lipoprotein (HDL) cholesterol; LDL-C, low-density lipoprotein (LDL) cholesterol; Lp(a), Lipoprotein(a); OR, odds ratio; RR, relative risk; TG, triglycerides.
Melo et al. reported higher levels of total cholesterol, LDL-cholesterol, triglycerides, and HDL-cholesterol. The altered lipid profile in endometriosis has been further investigated by several reports and yielded inconsistent results. Tan et al. effectively addressed these varying results in a recent analysis of nine studies investigating the RR of dyslipidaemia among women with endometriosis. Overall, these studies were limited by a small number of patients, differences in both parameters measured, and timing of measurements; therefore, these results should be interpreted with caution.

A preclinical study demonstrated altered serum lipid profiles in mice with endometriosis. Later reports confirmed that dysregulated phospholipid and sphingolipid metabolism plays a key role in endometriosis pathogenesis. Sphingolipids serve as biologically active components of cell membranes and are involved in many processes, such as proliferation, maturation, and apoptosis. Lee et al. provided evidence of altered sphingolipid metabolism flux in the serum, peritoneal fluid, and endometrial tissue of women with endometriosis. They observed up-regulation of specific sphingolipid enzymes (sphingomyelin synthase 1, sphingomyelinase 3, and glucosylceramide synthase) in endometriotic debris, with corresponding increased glucosylceramide, decreased sphingomyelin levels, and decreased apoptosis in the endometrium. Ceramides act as second messengers in activating the apoptotic cascade and precursors for many other sphingolipids. Elevated ceramide levels were evidenced in the peritoneal fluid of infertile endometriotic women, triggering reactive oxygen species formation, and leading to oocytotoxicity. Similarly, several investigations have suggested a pivotal role for sphingolipids in the pathogenesis of myocardial infarction, hypertension, stroke, and diabetes. This set of evidence suggests that sphingolipids may function as mediators of interorgan and intercellular communication. Future studies are warranted to investigate the role of sphingolipids in endometriosis and investigate whether endometriosis-induced sphingolipids promote a systemic pro-inflammatory and pro-oxidant cascade, which then leads to dysfunction of other organs including those associated with the cardiovascular system.

**Obesity**

An inverse relationship between endometriosis and body mass index (BMI) is commonly acknowledged, although some studies of limited impact have reported otherwise. Reduction in the adipose stem cell population, an anorexigenic effect through altered hepatic gene expression, and promotion of lipid dysfunction and fat loss are key mechanisms thought to be involved in the clinically low BMI phenotype observed in women with endometriosis.

**Smoking, air pollution exposure, and diabetes**

While tobacco smoking is an established risk factor for ischaemic heart disease, its relationship with endometriosis is puzzling. Indeed, intense variation and conflicting data regarding the association between smoking and endometriosis have been reported. Several studies have suggested that smoking may be associated with a decreased risk of endometriosis, but recently published data dismissed any link between endometriosis and tobacco smoking habits. Similarly, the association between endometriosis and pollution exposures remains speculative. Only one study from NHISII showed no increased risk for endometriosis with regards to air pollution exposure.

Despite the potential overlap in the molecular pathways between endometriosis and diabetes, namely type 1, there is no robust evidence for an association between diabetes and endometriosis to date. Indeed, no association between laparoscopically confirmed endometriosis and risk of type 2 diabetes risk in a multivariable analysis could be evidenced in the NHISII. The risk of gestational diabetes mellitus among women with endometriosis remains controversial with discordant data across studies and meta-analyses.

**Endometriosis and cardiovascular disease**

**Endometriosis and ischaemic burden (coronary artery disease and stroke)**

The first hint suggesting a possible association between ischaemic heart disease and inflammation of the upper genital tract came with evidence that women with pelvic inflammatory disease are more likely to have myocardial infarction and stroke than the general population. A limited number of studies suggested an association between endometriosis, coronary artery disease (CAD), and stroke. Only two large population-based cohort studies have shown an association between ischaemic heart disease and endometriosis (Table 2). Okoth et al. conducted a retrospective study of 279 759 women (1995–2018) and found an aOR of 1.24 (95% CI 1.13–1.37) for a composite endpoint of ischaemic heart disease, heart failure (HF), and cerebrovascular disease if endometriosis was present. In addition, endometriosis was associated with a 1.40-fold (95% CI 1.22–1.61) increased risk for ischaemic heart disease and a 1.19-fold (95% CI 1.04–1.36) increased risk for cerebrovascular disease. Similarly, NHISII included 116 430 US women (1989–2009) and found a 52% greater risk for myocardial infarction (RR 1.52; 95% CI 1.13–1.37) for a composite endpoint of ischaemic heart disease, heart failure (HF), and cerebrovascular disease if endometriosis was present. In addition, endometriosis was associated with a 1.62-fold (95% CI 1.39–1.89) increased risk of the composite of myocardial infarction, angiographically confirmed angina, and revascularization either by coronary artery bypass graft surgery or by percutaneous coronary intervention. It is worth noting that co-occurring endometriosis among women with myocardial infarction did not translate into worse in-hospital outcomes.

The association of endometriosis with the prevalence and incidence of CVD appears likely from the aforementioned studies, but...
Table 2  Description of large-scale studies on observed associations between endometriosis and cardiovascular disease

| Author(s)       | Study name                  | Location | Population                                                                 | Design                                  | Method of data collection | Ascertainment period (year) | Findings                                                                                           |
|-----------------|-----------------------------|----------|----------------------------------------------------------------------------|-----------------------------------------|----------------------------|-----------------------------|------------------------------------------------------------------------------------------|
| Okoth et al.    | UK                          | Women aged between 16 and 50. 56 090 women with endometriosis and 223 669 matched control women | Population-based cohort study           | Electronic health records           | 1995–2018                  | Endometriosis composite outcome: IHD, HF, cerebrovascular disease (aHR, 1.24; 95% CI 1.13–1.37) IHD (aHR 1.40; 95% CI 1.22–1.61); cerebrovascular disease (aHR, 1.19; 95% CI 1.04–1.36); arrhythmia (aHR, 1.26; 95% CI 1.11–1.43) |
| Mu et al.       | NHSII (Nurses’ Health Study II) | USA      | 116 430 female nurses aged 25–42. 4244 women with laparoscopically confirmed endometriosis and 91 554 control women | Prospective cohort study               | Self-completed questionnaire | 1989–2009                  | Myocardial infarction (RR, 1.52, 95% CI 1.17–1.98); angiographically confirmed angina (RR 1.91, 95% CI 1.59–2.29); CABG/coronary angioplasty procedure/stent (RR 1.35, 95% CI 1.08–1.69) |
| Chiang et al.   | Taiwan                      | Women aged between 18 and 50. 17 543 women with endometriosis and 70 172 matched control women | Retrospective population-based cohort   | Electronic health records           | 1997–2013                  | Composite outcome: Myocardial infarction, HF, stroke (aHR 1.17, 95% CI 1.05–1.29)          |
| Sugiura-Ogasawara et al. | Japan Environment and Children’s Study (JECS) | Japan     | 103 070 pregnancies                                                      | Prospective cohort study               | Self-completed questionnaire | January 2011 to March 2014          | Endometriosis is independent predictors for VTE (OR 2.70, 95% CI 1.21–6.00)               |

aHR, adjusted hazard ratio; CABG, coronary artery bypass graft; HF, heart failure; IHD, ischaemic heart disease; OR, odds ratio; RR, relative risk; VTE, venous thrombo-embolic events.
after considering the advances all these studies bring to the field, their limitations must also be considered. First, the populations studied were primarily Caucasian Europeans, limiting the generalizability of the evidence to other ethnicities. Despite efforts to harmonize these datasets, there are inevitable inconsistencies, including known and unknown factors, across these reports. For instance, the definitions of endometriosis (e.g. surgically confirmed, clinical suspicion, etc.) and CAD (e.g. acute myocardial infarction, coronary stenosis, etc.) varied widely across studies. This inhomogeneity among definition added uncertainty to the cardiovascular endpoints, particularly because the pathophysiology of acute myocardial infarction (plaque rupture and thrombosis) is not the same as the process of stable CAD. Furthermore, some observational cohorts inconsistently shared control groups.

Second, hysterectomy in women aged 50 years or younger has been associated with a significantly increased risk of ischaemic heart disease, with oophorectomy linked to an increased risk of both CAD and stroke.\(^{96,97}\) Similar risk was evidenced in the NHSII cohort,\(^{92}\) as 42% of the association between CAD and endometriosis was potentially explained by the greater frequency of hysterectomy/oophorectomy and earlier age at surgery following an endometriosis diagnosis. Accordingly, the adverse outcome portended by hysterectomy regardless of oophorectomy status was associated with the adverse risk factor profile of women who underwent hysterectomy.\(^{98}\)

Finally, the role of hormonal treatment strategies for endometriosis, including combined oral contraceptives, progestins, and gonadotrophin-releasing hormone (GnRH) analogues, has been highly questioned regarding a potentially enhanced lipid profile,\(^{99}\) cardiovascular risk profile, and weight gain.\(^{100–102}\)

### Endometriosis and venous thrombo-embolic events

Systemic inflammation is known to up-regulate procoagulant factors, increase platelet reactivity, and favour thrombo-embolic events.\(^{103}\) As such, endometriosis was initially defined as a hormonal-dependent and inflammatory disease to perfectly link inflammation and thrombosis; however, the current picture differs substantially from this simplistic model. Basic research and evidence reporting an enhanced prothrombotic and inflammatory state in endometriosis did not translate into a clinically increased risk of venous thrombo-embolic events (VTE).

A review of the literature discloses several studies reporting an association between endometriosis and a procoagulant state. High tissue factor expression,\(^{104}\) increased procoagulant microparticle levels,\(^{39}\) and modest systemic changes of coagulation parameters\(^{105}\) have been reported, but these variables did not translate into increased VTE rates. To date, no studies have shown that endometriosis is associated with an increased risk of VTE except during pregnancy. Only anecdotal case series reported episodes of VTE mainly favoured by extrinsic compression, pelvic mass, and immobilization.\(^{106–109}\) However, careful attention should be paid to pregnant women with endometriosis. In a nationwide Japanese birth cohort study of 103 070 pregnancies, the frequency of VTE was 7.5 per 10 000 women during the pregnancy and post-partum period. Endometriosis and recurrent pregnancy loss were identified as novel independent risk factors for VTE.\(^{75}\)

Regarding pregnancy, these results indicate that there is either no or a weak, direct interaction between VTE and endometriosis. Assisted reproductive techniques and, most notably, exogenous hormones are nonetheless key indirect contributors to the risk of venous thrombosis and ischaemic endpoints (Myocardial infarction, stroke, etc.) in endometriosis.\(^{110,111}\) Although successful fertility therapy was not associated with an increased risk of CVD later in life in the general population,\(^{111}\) recent updated studies reported assisted reproductive techniques increased the risk of venous thrombosis in women with endometriosis.\(^{112}\)

### Endometriosis, arrhythmias, and heart failure

The literature is limited regarding HF and arrhythmias in endometriosis. Only one study conducted by Okoth et al.\(^{47}\) examined the association between endometriosis and several cardiovascular outcomes including HF and arrhythmia, in a large UK retrospective matched cohort study. They found that endometriosis was associated with a higher risk of arrhythmia (adjusted HR 1.26; 95% CI 1.11–1.43; \(P = 0.001\)). The noxious impact of chronic inflammation has been proposed by the authors to explain the association between endometriosis and arrhythmia. These results should be interpreted with caution, as no reference is made to the type of arrhythmia and several well-known cofactors associated with arrhythmia onset were omitted from the model (left ventricular ejection fraction, sleep disorders, treatment strategies in particular hormonal treatments, hysterectomy/oophorectomy status, dietary patterns, physical activity, inflammatory biological burden, etc.). Furthermore, cancer antigen-125, a well-established tumour biomarker related to ovarian cancer, has been associated with endometriosis\(^{113}\) and more recently with HF\(^{114,115}\) and new-onset atrial fibrillation (AF).\(^{116,117}\) To date, there is insufficient evidence to suggest a causal relationship between endometriosis or arrhythmias and HF.

### Endometriosis and cardiovascular pharmacology

Several cardiovascular medications have been tested in animal models, with promising results on the establishment and maintenance of endometriotic lesions. However, their translation into human clinical trials has been very limited.

Statins, classically known for their roles in lowering cholesterol and anti-inflammatory properties, have been shown to play a role in endometriosis by modifying cell signalling in preclinical studies using human endometriotic stromal cell cultures. Statins therapy lead to increased apoptosis, decreased proliferation, and impaired cell adhesion and motility.\(^{118,119}\) Additionally, statins inhibited stromal cell invasion and reduced angiogenesis.\(^{120–122}\) Recent findings showed that platelets play important roles in the development of endometriosis in general and in fibrogenesis in particular.\(^{123,124}\) Antiplatelet treatment was demonstrated to impede the progressive epithelial-mesenchymal transition, fibroblast-to-myofibroblast transdifferentiation, and smooth muscle metaplasia, resulting in reduced lesion size of endometriotic lesions and fibrogenesis.\(^{125}\) Low-dose aspirin, used in a preclinical setting, has lately been proposed for its ability to
down-regulate progesterone resistance and a target for endometriosis-related infertility.\textsuperscript{125}

Women with endometriosis tend to have higher levels of psychological stress, which is known to promote tumour growth and metastasis. B-Adrenergic receptor blockade in a mouse model of endometriosis completely abolished the promotional effect of chronic stress, through suppression of ADRB2 and CREB activation, thus suppressing angiogenesis and proliferation.\textsuperscript{126} Additionally, peroperative use of propranolol in a mouse model of endometriosis significantly decelerated the growth of residual lesions that were intentionally left out during the primary surgery.\textsuperscript{127} Similarly, telmisartan inhibited vascularization, immune cell content, and growth of murine endometriosis-like lesions.\textsuperscript{128,129}

**Summary and authors’ perspectives**

Cardiovascular disease remains the leading cause of mortality among women, causing 1 in 3 deaths each year,\textsuperscript{130} whereas endometriosis affects 1 in 10 reproductive-age women. This unequivocal epidemiological observation should be considered in the field of future cardiovascular research in women. Current clinical evidence is insufficient to implicate a strong association and potential role for endometriosis in CVD.

The literature is sparse regarding the association between CVD and endometriosis (Graphical Abstract). The epidemiologically observed associations between the two should be interpreted with caution for several reasons. Current evidence is limited by small sample sizes, observational designs, and the specific characteristics of the population from which the samples are derived (high-income countries, cohort study of hospital-based healthcare workers, primarily Caucasian Europeans, etc.). Only small associations between endometriosis and CVD have been reported in the literature, although inconsistently. Representation of participants with endometriosis in cardiovascular clinical trials and registries is challenging, as endometriosis remains under-recognized. Endometriosis is usually diagnosed in higher socioeconomic groups and likely related to inequities in access to health care. In addition to socioeconomic impact, multiple factors can be identified as barriers to inclusion of women with endometriosis in CV studies: misdiagnosis is common; as diagnosis remains challenging and largely delayed by years; unawareness about ongoing trials, combined cardiac and gynaecologic care, and monitoring in clinical trials, etc. The chronic and heterogeneous nature of endometriosis (e.g. disease stage and lesion type) and the confounding influence of hormonal, non-hormonal, and pain-related interventions further complicate the cause-and-effect relationship in CV endpoints.

Cardiovascular disease risk estimation remains challenging, especially in women with endometriosis. Further research is needed to better understand how endometriosis should be incorporated into risk prediction models alongside well-established risk factors. Indeed, the reduced quality of life and psychosocial risk factors such as depression and anxiety may overlap and help to explain the predisposition for CVD. In considering women with endometriosis, there is a need to better understand the potential associations with CVD and risk factors and to clarify the pathophysiology of the female heart at a broader level (Graphical Abstract).

Inclusivity is therefore mandatory, and specific registries, studies, and trials are urgently needed to address the underlying biological mechanisms potentially shared between CVD and endometriosis, clarify whether endometriosis can cause CVD; assess the prognosis of endometriosis in cardiovascular patients, and finally, advance potential innovative solutions and tailored management of CVD in women with endometriosis.

Multicentre case-controlled and cross-sectional studies may be of particular interest in women admitted to cardiology departments to ascertain the association between endometriosis and various CVDs (ischaemic cardiomyopathy, HF, AF, etc.) and risk factors. However, the benefits of such study designs are limited by the fact that (i) endometriosis is greatly underdiagnosed, (ii) there are asymptomatic cases, and (iii) the assessment of specific CVD phenotypes and risk factors distributions among endometriosis patients necessitates a large sample. Only international and/or national levels initiatives may have the power to address the prevalence, links, impact, and prognosis of endometriosis and CVD by analysing data from large-scale surveys. Strong evidence regarding the association between these two conditions obtained from large-scale cohorts or large population-based studies, may contribute to a change in the prevention, screening, early detection, and treatment of CV risk factors among women with endometriosis.

**Lead author biography**

Dr Benjamin Marchandot is a general cardiologist in the Cardiac Care Unit (CCU) at Strasbourg University Hospital, France. He is a member of Strasbourg Cardiovascular Research Group—GERCA (Groupe pour l’Enseignement et la Recherche Cardiovasculaire en Alsace), a multidisciplinary research team involved in the field of CVD, thrombosis, and haemostasis.

**Conflict of interest:** The authors declare that there is no conflict of interest regarding the publication of this article. O.M. received institutional research grants from Fondation Coeur et Vaisseaux, AstraZeneca and Boehringer Ingelheim. K.M. received a grant from Edwards Lifesciences (THV-F20-142). The manuscript has been read and approved for submission by all authors. The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

**Funding**

This work was supported by Groupe pour l’Enseignement, la PrÉvention et la Recherche Cardiologique en Alsace (GERCA).

**Data availability:** No new data were generated or analysed in support of this research.

**References**

1. Shafrir AL, Farland LV, Shah DK, Harris HR, Kvaskoff M, Zondervan K, Missmer SA. Risk for and consequences of endometriosis: a critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol 2018;31:1–15.

2. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet 2021;397:839–852.
Endometriosis and cardiovascular disease

1. Maas AHEM, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kudanid V, Leen E, Laminoundi I, Maclaran K, Panay N, Stevenson JC, van Trotsenburg M, Collins P. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42:967–984.

2. Zondervan KT, Becker CM, Mismmer SA. Endometriosis. N Engl J Med 2020;382:1244–1256.

3. Parazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol 2017;209:3–7.

4. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol 2019;15:666–682.

5. Parazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol 2017;209:3–7.

6. Guerriero S, Condous G, van den Bosch T, Valentin L, Leone FP, Van Hoof PA, Duga S, Marziliano N, Denny JC, Shaffer C, El-Mokhtari NE, Franke A, Braund PS, van Capelleveen JC, Doney ASF, Donnelly LA, Asselta R, Merlini A, Auer PL, Schick UM, Lu Y, Zhang H, Dube M-P, Goel A, Farrall M, Peloso GM, Betsholtz C, Ruusalepp A, Franzén K, Ko¨nig IR, Eicher JD, Johnson AD, Hamby SE, Kooperberg C, Jackson RD, Stahl E, Müller-Nurasyid M, Strauch K, Varga TV, Waldenberger M, Zeng L, Chowdhury R, Salomaa V, Ford I, Jukema JW, Arterioscler Thromb Vasc Biol 2015;35:711–715.

7. Kinugasa S, Shinohara K, Watanuki K. Increased asymmetric dimethylarginine and enhanced inflammation are associated with impaired vascular reactivity in women with endometriosis. Atherosclerosis 2011;219:784–788.

8. Santos L, D’Onofrio F, Campo S, Ferraro PM, Nappi L. Oxidative stress and endometriosis: a systematic review of the literature. Oxid Med Cell Longev 2017:1–10.

9. Rey J-M, Bettesh C, Schettler H, Kaser G, Ruess B, Mehta S, Maas P, van Eijk J, Alveras M, Vitale N, Infante T, Mancini FP. Role of estrogen receptor-β in the pathogenesis of endometriosis. Hum Reprod 2019;34:2051–2060.

10. Bazot M, Daraï E. Diagnosis of deep endometriosis: clinical examination, ultrasound, magnetic resonance imaging, and other techniques. Fertil Steril 2017;108:S86–S94.

11. Guerriero S, Ajossa S, Rodriguez I, Mais V, Alcazar JL. Intraperitoneal immune cell status in infertile women with and without endometriosis. J Reprod Immunol 2015;106:39–51.

12. Zondervan KT, Becker CM, Mismmer SA. Endometriosis. N Engl J Med 2020;382:1244–1256.

13. Van den Bosch T, Van Schoubroeck D. Ultrasonographic diagnosis of endometriosis and adenomyosis: state of the art. Best Pract Res Clin Obstet Gynaecol 2018;51:16–24.

14. Guerriero S, Condos G, van den Bosch T, Valentin L, Leone PP, Van Schoubroeck D, Exacoustos C, Installé AJ, Martins WP, Abrao MS, Hudelet G, Bazot M, Alcazar JL, Goncalves MO, Pascual MA, Apo B, Saveli L, Dunham R, Reid S, Menakaya U, Bourne T, Ferrari S, Leon M, Bignardi T, Holland T, Jurkovic D, Benacerraf B, Osuga Y, Somigliana E, Timmerman D. Systematic approach to sonographic diagnosis of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Assessment (IDEA) group. Ultrasound Obstet Gynecol 2016;48:318–332.

15. Van den Bosch T, Van Schoubroeck D. Ultrasonographic diagnosis of endometriosis and adenomyosis: what goes wrong in endometriosis? Int J Mol Sci 2019;20:886–894.

16. Ahn SH, Khalaj K, Young SL, Lessey BA, Kati M, Tayade C. Immune-inflammation gene signatures in endometriosis patients. Fertil Steril 2016;106:1420–1431.e7.

17. Symons LK, Miller JE, Kay VR, Marks RM, Liblik K, Kati M, Tayade C. The immune-nophathophysiology of endometriosis. Trends Mol Med 2018;24:748–762.

18. Tariverdian N, Sedettop F, Ruckie M, Bosim SM, Klapp BF, Kentenich H, Arck PC. Intraperitoneal immune cell status in infertile women with and without endometriosis. J Reprod Immunol 2009;80:80–90.

19. Saunders PTK. Home AW. Endometriosis: Etiology, pathology, and therapeutic prospects. Cell 2021;184:2807–2824.

20. Han SJ, Jung SY, Wu SP, Hawkins SM, Kyo S, Qin J, Lydon JP, Tsai SY, Tsi M, DeMayo FJ, O’Malley BW. Estrogen receptor β mediates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell 2015;163:960–974.

21. Bulan SE, Monsavas D, Pavone ME, Dynon M, Xue Q, Attar E, Tokunaga H, Su EJ. Role of estrogen receptor-β in endometriosis. Semin Reprod Med 2012;30:39–45.

22. Scutiero G, Iannone P, Bernardi G, Bonaccorsi G, Spadaro S, Volta CA, Greco MP, Nappi L. Oxidative stress and endometriosis: a systematic review of the literature. Oxid Med Cell Longev 2017;2017:1–7.

23. Munro’s J, Martínez-Zamora MA, Tássies D, Coloma JL. Torrente MA, Reverter JC, Carmona F, Balsalú J. Total circulating microparticle levels are increased in patients with deep infiltrating endometriosis. Hum Reprod 2017;32:325–331.

24. Zondervan KT, Becker CM, Koga K, Mismmer SA, Taylor RN, Vigna P. Endometriosis. Nat Rev Dis Primers 2018;4:9.
43. Ou M, Li X, Zhao S, Cui S, Tu J. Long non-coding RNA CDKN2B-AS1 contrib-
45. Mu F, Rich-Edwards J, Rimm EB, Spiegelman D, Forman JP, Missmer SA. 
47. Pillet M-CL, Schneider A, Borghese B, Santulli P, Souza C, Streuli I, de Ziegler 
49. Farland LV, Missmer SA, Bijon A, Gusto G, Gelot A, Clavel-Chapelon F, 
51. Melo AS, Rosa e, Silva JC, Rosa e, Silva AC, Poli-Neto OB, Ferriani RA, Vieira 
53. Hopeman MM, Riley JK, Frolova AI, Jiang H, Jungheim ES. Serum polyunsatur-
55. Verit FF, Erel O, Celik N. Serum paraoxonase-1 activity in women with endo-
57. Santos E, Leite V, Uchoa AL, de Freitas MT, Barbosa AM, Horta MG, Soli 
61. Okoth K, Wang J, Zemedikun D, Thomas GN, Nirantharakumar K, Adderley 
63. Okoth K, Wang J, Zemedikun D, Thomas GN, Nirantharakumar K, Adderley 
65. Cramer DW, Wilson E, Stillman RJ, Berger MJ, Belisle S, Schiff I, Albrecht B,
67. Okoth K, Wang J, Zemedikun D, Thomas GN, Nirantharakumar K, Adderley 
69. Okoth K, Wang J, Zemedikun D, Thomas GN, Nirantharakumar K, Adderley 
71. Okoth K, Wang J, Zemedikun D, Thomas GN, Nirantharakumar K, Adderley 
73. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovas-
75. Santoro L, D’Onofrio F, Flore R, Gasbarrini A, Santoliquido A. Endometriosis 
77. Letsiou S, Peterse DP, Fassbender A, Hendriks MM, van den Broek NJ, Berger 
79. Simmen RCM, Brown DM, Quick CM, Alhallak I, Rose TK, Liu S, Kelley AS. Co-
81. Lee YH, Yang JX, Allen JC, Tan CS, Chern BSM, Tan TY, Tan HH, Mattar CNZ, 
83. Goetz TG, Mamillapalli R, Taylor HS. Low body mass index in endometriosis is 
85. Goetz TG, Mamillapalli R, Taylor HS. Low body mass index in endometriosis is 
87. Bellelis P, Podgaec S, Br 
89. Simmen RCM, Brown DM, Quick CM, Alhallak I, Rose TK, Liu S, Kelley AS. Co-
91. Aban M, Ertunc D, Tok EC, Tamer L, Arslan M, Dilek S. Modulating interaction 
93. Malangoni S, Liu J, Hookey K, Ng T, Zhou H, Ma Y, Li H, Gao Z, Li Z, Xia 
95. Mahalingaiah S, Hart JE, Fenwick D, Bala CN, Zou J, Pohl G, Wieland G, Le 
97. Mahalingaiah S, Hart JE, Fenwick D, Bala CN, Zou J, Pohl G, Wieland G, Le 
99. Mahalingaiah S, Hart JE, Fenwick D, Bala CN, Zou J, Pohl G, Wieland G, Le 
101. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
103. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
105. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
107. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
109. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
111. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
113. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
115. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
117. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
119. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
121. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
123. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
125. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
127. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
129. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
131. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
133. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
135. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
137. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
139. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
141. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
143. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
145. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
147. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
149. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
151. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
153. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
155. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
157. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
159. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee 
161. Han JY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee JH, Park SY, Lee
Endometriosis and cardiovascular disease

91. Liu T-H, Wu C-W, Hao W-R, Hsu M-I, Liu J-C, Lin H-W. Risk of myocardial infarction in women with pelvic inflammatory disease. Int J Cardiol 2013;167:416–420.

92. Mu F, Rich-Edwards J, Rimberg B, Spiegelman D, Mismeier SA. Endometriosis and risk of coronary heart disease. Circ Cardiovasc Qual Outcomes 2016;9:257–264.

93. Chiang Hij, Lan KC, Yang YH, Chiang Jf, Kung FT, Huang fj, Lin Yj, Su Yt, Sung PH. Risk of major adverse cardiovascular and cerebrovascular events in Taiwanese women with endometriosis. J Formos Med Assoc 2021;120:327–336.

94. Akinjero A, Adegbala O, Akinyemiju T. Abstract P230: co-occurring endometriosis among women with myocardial infarction associated with worse in-hospital outcomes? findings from the nationwide inpatient sample. Circulation 2017;135:AP320.

95. Sugura-Ogawa M, Ebata T, Matsuki T, Yamada Y, Oomori T, Matsumoto Y, Kata S, Kano H, Kunbara T, Sato S, Kamiya M; the Japan Environment & Children’s Study (JECs) Group. Endometriosis and recurrent pregnancy loss as new risk factors for venous thromboembolism during pregnancy and postpartum: the JECs birth cohort. Thromb Haemost 2019;119:606–617.

96. Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J 2011;32:745–750.

97. Laughi-Tommaso SK, Khan Z, Weaver AL, Smith CY, Roca WA, Stewart EA. Cardiovascular and metabolic morbidity after hysterectomy with ovarian conservation: a cohort study. Menopause 2018;25:483–492.

98. Howard BV, Kuller L, Manson J, Wang Z, Poston L, Hudes G, Koshiyama P, Hrapchak B, Harris TB, Ockene JS. Women’s Health Initiative: Risk of cardiovascular disease after hysterectomy status, with and without oophorectomy. The Women’s Health Initiative Observational Study. Circulation 2005;111:1462–1470.

99. Farish E, Fletcher CD, Barnes JF, Mack A, Gray CE, Hart DM. Reversible menopause induced by the GnRH analogue buserelin: evidence on lipoxygen metabolism. Acta Endocrinol (Copenh) 1992;127:123–126.

100. Ferroero R, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother 2018;19:1109–1125.

101. Bertland N, Somigliana E, Viganò P, Vercellini P. Safety of medical treatments for endometriosis. Expert Opin Drug Saf 2016;15:21–30.

102. Yim SF, Lau TK, Saha SC, Chuang TK, Chang AM, Haines CJ. Prospective randomized study of the effect of ‘add-back’ hormone replacement on vascular function during treatment with gonadotropin-releasing hormone agonists. Circulation 1998;98:1631–1635.

103. Rees CT. Inflammation and thrombosis. J Thromb Haemost 2003;1:1343–1348.

104. Epelboin S, Labrosse J, Fauque P, Levy R, Gervoise-Boyé MJ, Devaux A, Bergré E, de Vienne C, Jonveaux P, De Mouzon J, Pessonneau F. Endometriosis and assisted reproductive technologies independently related to mother-child morbidity: a French longitudinal national study. Reprod Biomed Online 2021;42:627–633.

105. Ottolina J, Bartimao L, Dolic C, Salmieri N, Schimberni M, Villanacci R, Viganò P, Cardinali M. Assessment of coagulation parameters in women affected by endometriosis: validation study and systematic review of the literature. Diagnostics (Basel) 2020;10:567.

106. Li M, Chen K, Jiang X, Li X, Liu H, Hu FB, Wu T, Wei S. Higher carbohydrate antigen 125 levels are associated with increased risk of coronary heart disease in elderly Chinese: a population-based case-control study. PLoS One 2013;8:e61328.

107. Yucei H, Kaya H, Zornu A, Yildirim K, Sancaeldar E, Gunels H, Kurt R, Ozgul U, Turgut OO, Yilmaz MB. Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation. Herz 2015;40:119–124.

108. Selenic H, Shimaomoto K, Takano M, Kimura M, Takazaki Y, Tatsumi F, Watanabe E, Jujo K, Ishizuka N, Kawama M, Higawa N. Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women. J Heart 2017;103:1368–1373.

109. Nasu K, Yuge A, Tsuno A, Narahara H. Simvastatin inhibits the proliferation and the contractility of human endometriotic stromal cells: a promising agent for the treatment of endometriosis. Fertil Steril 2009;92:2097–2099.

110. Kobayashi A, Wang DH, Cress A, Pietrowski PC, Rezopczynska I, Villanueva J, Dubela AJ. Simvastatin induces apoptosis and alters cytokine levels in endometrial stromal cells. J Clin Endocrinol Metab 2010;95:3453–3459.

111. Esfandiani N, Khazaei M, Aij J, Bielecki R, Gotlieb L, Ryan E, Casper RF. Effect of a statin on an in vitro model of endometriosis. Fertil Steril 2007;88:257–262.

112. Sharma I, Dhawan V, Mahajan N, Sala SC, Dhalal LN. In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells. Fertil Steril 2010;94:1639–1646.e1.

113. Soares SR, Martinez-Varea A, Hidalgo-Mora J, Pellicer A. Pharmacological therapies in endometriosis: a systematic review. Fertil Steril 2012;98:529–555.

114. Zhang Q, Liu X, Guo SW. Progressive development of endometriosis and its hindrance by anti-platelet treatment in mice with induced endometriosis. Reprod Biomed Online 2017;34:124–136.

115. Guo SW, Ding D, Liu X. Anti-platelet therapy is efficacious in treating endometriosis induced in mouse. Reprod Biomed Online 2016;33:484–499.

116. Wang L, Zhang J, Zhang H, Li R, Li C, Zhao X, Li M. Low-dose aspirin can downregulate progesterone resistance and increase the expression of LIF in endometriosis during the implantation window. Gynecol Endocrinol 2021;37:725–729.

117. Long Q, Liu X, Qi Q, Guo SW. Chronic stress accelerates the development of endometriosis in mouse through adrenergic receptor β2. J Hum Reprod 2016;31:2506–2519.

118. Long Q, Zheng H, Liu X, Guo SW. Perioperative intervention by β-blockade and NfκB suppression reduces the recurrence risk of endometriosis in mice via incomplete excision. Reprod Sci 2019;26:697–708.

119. Nenciu A, Körbel C, Gu Y, Menger MD, Laschke MW. Combined blockage of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. J Hum Reprod 2014;29:1011–1024.

120. Nenciu A, Gu Y, Körbel C, Menger MD, Laschke MW. Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions. Br J Pharmacol 2017;174:2623–2635.

121. Virani SS, Alonso A, Pariaso A, Benjamin EJ, Budoff MJ, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Eskin MV, Everson KR, Ferguson JJ, Gupta DK, Khan SS, Kissela BM, Knudtson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lustey PL, Ph J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stakes A, VanWagner LB, Wang NY, Tao CW. On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 2021;143:e254–e743.